Stevens' Cure (Umckaloabo) emerged as a patent medicine claiming to treat tuberculosis in the United Kingdom at the beginning of the 20th century. However, due to its identity being shrouded in secrecy, it was never truly accepted by the medical community. It was "rediscovered" in the 1970s and subsequently developed into a very popular and successful phytopharmaceutical for the treatment of upper respiratory tract infections. Whether Stevens' Cure contained the same ingredient(s) as the modern Umckaloabo has not yet been demonstrated. We attempted to elucidate for the first time the identity of the original ingredient by comparative analysis of historical product samples. Three historical samples of Stevens' Cure were compared with DC. and Curt. root per UPLC-MS analysis. We confirm that the ingredient- DC.-is indeed the same as used in modern phytotherapy. We also attribute the first ethnopharmacological record of DC. being used for the treatment of tuberculosis to C. H. Stevens, the "creator" of Umckaloabo.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10791834 | PMC |
| http://dx.doi.org/10.3389/fphar.2023.1294997 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN-GIL hybrid single-molecule inhibitors.
Eur J Med Chem
December 2024
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine St., Baltimore, MD, 21201, USA; University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center, 22 S. Greene St., Baltimore, MD, 21201, USA. Electronic address:
Current treatments for acute myeloid leukemias (AMLs) cure fewer than 30 % of patients. This low efficacy is due, in part, to the inter-patient and intra-patient heterogeneity of AMLs; accordingly, all current AML treatment regimens involve drug combinations (polypharmacy). A recently-completed clinical trial in relapsed/refractory AML using a combination of two newer targeted antileukemics, the BCL-2 inhibitor venetoclax (VEN) plus the FLT3 inhibitor gilteritinib (GIL), yielded highly promising results for this two-drug polypharmacy combination.
View Article and Find Full Text PDFNoninvasive Mechanical Ventilation Is a Promising Way to Improve Lung Cancer Radiation Therapy.
Adv Radiat Oncol
February 2025
Department of Radiation Oncology, Amsterdam UMC location Free University, Amsterdam, The Netherlands.
Purpose: Accurate radiation therapy (RT) for lung cancer is challenging because of the respiratory motion of the tumor and surrounding organs at risk. Recently, non-invasive mechanical ventilation (NIMV) has been investigated as a novel respiratory motion management strategy. Using NIMV, respiratory motion can be minimized, while a larger lung volume yields less overall lung dose.
View Article and Find Full Text PDFCopper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma.
Nat Commun
December 2024
School of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Article Synopsis
- Anti-GD2 antibody therapy offers benefits for neuroblastoma patients, but its effectiveness is limited by the tumor's immunosuppressive environment.
- Research shows that using copper chelation can enhance this therapy by improving immune responses, specifically by boosting the activity of neutrophils that help fight the tumor.
- The study suggests repurposing the approved copper chelator Cuprior as a safe and effective method to improve the outcomes of anti-GD2 therapy in neuroblastoma patients.
Inflammation and DNA methylation in Alzheimer's disease: mechanisms of epigenetic remodelling by immune cell oxidants in the ageing brain.
Redox Rep
December 2024
Department of Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand.
Alzheimer's disease is a neurodegenerative disease involving memory impairment, confusion, and behavioural changes. The disease is characterised by the accumulation of amyloid beta plaques and neurofibrillary tangles in the brain, which disrupt normal neuronal function. There is no known cure for Alzheimer's disease and due to increasing life expectancy, occurrence is projected to rise over the coming decades.
View Article and Find Full Text PDFUnexpected peritoneal metastases diagnosed at the time of primary colon cancer resection: controversies regarding options for management.
J Gastrointest Oncol
October 2024
Department of Colorectal Surgery, Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, FL, USA.
Peritoneal metastases synchronously occurring in the patient with primary colon cancer causes that patient to be at high risk for subsequent disease progression within the abdomen and pelvis. If peritoneal metastases are preoperatively diagnosed, patients are likely to be treated with neoadjuvant chemotherapy with or without biological therapy prior to cytoreductive surgery (CRS). However, if one only considers patients with peritoneal metastases unexpectedly identified at the time of primary colon cancer resection, the optimal management strategy is neither standardized nor evidence based.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!